272 related articles for article (PubMed ID: 3436111)
1. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Lønning PE; Kvinnsland S; Thorsen T; Ueland PM
Clin Pharmacokinet; 1987 Dec; 13(6):393-406. PubMed ID: 3436111
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
Lønning PE; Johannessen DC; Thorsen T
Br J Cancer; 1989 Jul; 60(1):107-11. PubMed ID: 2553085
[TBL] [Abstract][Full Text] [Related]
3. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
4. Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Lønning PE; Kvinnsland S; Thorsen T; Ekse D
Breast Cancer Res Treat; 1986; 7 Suppl():S77-82. PubMed ID: 3742065
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous or intra-amniotic injection of dehydroepiandrosterone sulphate on oestrogen levels in urine and serum in late pregnancy with live anencephalic foetuses.
Maeyama M; Ichimaru S; Nakahara K; Nakayama M; Miyakawa I
J Endocrinol; 1976 Dec; 71(3):305-13. PubMed ID: 137266
[TBL] [Abstract][Full Text] [Related]
6. Low-dose aminoglutethimide in treatment of advanced breast cancer.
Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum oestrogen concentrations in post-menopausal women taking oestrone sulphate and oestradiol.
Anderson AB; Sklovsky E; Sayers L; Steele PA; Turnbull AC
Br Med J; 1978 Jan; 1(6106):140-2. PubMed ID: 620226
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
9. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.
Samojlik E; Santen RJ; Worgul TJ
Clin Endocrinol (Oxf); 1984 Jan; 20(1):43-51. PubMed ID: 6692582
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration.
Schindler AE; Bolt HM; Zwirner M; Hochlehnert G; Göser R
Arzneimittelforschung; 1982; 32(7):787-91. PubMed ID: 6289846
[TBL] [Abstract][Full Text] [Related]
11. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide.
Lønning PE; Skulstad P
J Steroid Biochem; 1989 Oct; 33(4A):565-71. PubMed ID: 2811366
[TBL] [Abstract][Full Text] [Related]
14. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
15. Role of aminoglutethimide in male breast cancer.
Harris AL; Dowsett M; Stuart-Harris R; Smith IE
Br J Cancer; 1986 Oct; 54(4):657-60. PubMed ID: 3778807
[TBL] [Abstract][Full Text] [Related]
16. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
Lønning PE
Cancer Chemother Pharmacol; 1990; 26(4):241-4. PubMed ID: 2369789
[TBL] [Abstract][Full Text] [Related]
17. The absorption and metabolism of oral oestradiol, oestrone and oestriol.
Townsend PT; Dyer GI; Young O; Whitehead MI; Collins WP
Br J Obstet Gynaecol; 1981 Aug; 88(8):846-52. PubMed ID: 6789863
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
19. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
20. Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
Harris AL
Exp Cell Biol; 1985; 53(1):1-8. PubMed ID: 3881300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
